Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2017 1
2018 2
2019 1
2020 1
2021 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Predictors of Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Receiving EGFR Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis.
Buonerba C, Iaccarino S, Dolce P, Pagliuca M, Izzo M, Scafuri L, Costabile F, Riccio V, Ribera D, Mucci B, Carrano S, Picozzi F, Bosso D, Formisano L, Bianco R, De Placido S, Di Lorenzo G. Buonerba C, et al. Among authors: ribera d. Cancers (Basel). 2019 Aug 28;11(9):1259. doi: 10.3390/cancers11091259. Cancers (Basel). 2019. PMID: 31466227 Free PMC article. Review.
Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. Sunitinib in Patients with Sarcomatoid Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.
Buonerba C, Dolce P, Iaccarino S, Scafuri L, Verde A, Costabile F, Pagliuca M, Morra R, Riccio V, Ribera D, De Placido P, Romeo V, Crocetto F, Longo N, Imbimbo C, De Placido S, Di Lorenzo G. Buonerba C, et al. Among authors: ribera d. Cancers (Basel). 2020 Feb 10;12(2):408. doi: 10.3390/cancers12020408. Cancers (Basel). 2020. PMID: 32050629 Free PMC article. Review.
The Management of Phaeochromocytomas and Paragangliomas in the Era of Precision Medicine: Where Are We Now? Evidence-Based Systemic Treatment Options and Future Cluster Oriented Perspectives.
Bracigliano A, Marretta AL, Guerrera LP, Simioli R, Clemente O, Granata V, Minopoli A, Della Vittoria Scarpati G, Picozzi F, Cannella L, Pizzolorusso A, Di Gennaro F, Tafuto R, Sarno MR, Cavalcanti E, Ribera D, Tafuto S. Bracigliano A, et al. Among authors: ribera d. Pharmaceuticals (Basel). 2024 Mar 8;17(3):354. doi: 10.3390/ph17030354. Pharmaceuticals (Basel). 2024. PMID: 38543140 Free PMC article. Review.
A risk-group classification model in patients with bladder cancer under neoadjuvant cisplatin-based combination chemotherapy.
Ferro M, Lucarelli G, de Cobelli O, Dolce P, Terracciano D, Musi G, Porreca A, Busetto GM, Del Giudice F, Soria F, Gontero P, Cantiello F, Damiano R, Crocerossa F, Abu Farhan AR, Autorino R, Vartolomei MD, Marchioni M, Mari A, Minervini A, Longo N, Celentano G, Chiancone F, Perdonà S, Del Prete P, Ditonno P, Battaglia M, Zamboni S, Antonelli A, Greco F, Russo GI, Hurle R, Crisan N, Manfredi M, Porpiglia F, Ribera D, De Placido P, Facchini S, Scafuri L, Verde A, Di Lorenzo G, Cosimato V, Luciano A, Caputo VF, Crocetto F, Buonerba C. Ferro M, et al. Among authors: ribera d. Future Oncol. 2021 Oct;17(30):3987-3994. doi: 10.2217/fon-2020-1298. Epub 2021 Jul 19. Future Oncol. 2021. PMID: 34278815
Assessment of Total, PTEN-, and AR-V7+ Circulating Tumor Cell Count by Flow Cytometry in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide.
Di Lorenzo G, Zappavigna S, Crocetto F, Giuliano M, Ribera D, Morra R, Scafuri L, Verde A, Bruzzese D, Iaccarino S, Costabile F, Onofrio L, Viggiani M, Palmieri A, De Placido P, Marretta AL, Pietroluongo E, Luce A, Abate M, Navaeiseddighi Z, Caputo VF, Celentano G, Longo N, Ferro M, Morelli F, Facchini G, Caraglia M, De Placido S, Buonerba C. Di Lorenzo G, et al. Among authors: ribera d. Clin Genitourin Cancer. 2021 Oct;19(5):e286-e298. doi: 10.1016/j.clgc.2021.03.021. Epub 2021 Apr 3. Clin Genitourin Cancer. 2021. PMID: 33958297
The Influence of Prednisone on the Efficacy of Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer.
Buonerba C, Sonpavde G, Vitrone F, Bosso D, Puglia L, Izzo M, Iaccarino S, Scafuri L, Muratore M, Foschini F, Mucci B, Tortora V, Pagliuca M, Ribera D, Riccio V, Morra R, Mosca M, Cesarano N, Di Costanzo I, De Placido S, Di Lorenzo G. Buonerba C, et al. Among authors: ribera d. J Cancer. 2017 Aug 22;8(14):2663-2668. doi: 10.7150/jca.20040. eCollection 2017. J Cancer. 2017. PMID: 28928853 Free PMC article.
Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study.
Gordon JA, Buonerba C, Pond G, Crona D, Gillessen S, Lucarelli G, Rossetti S, Dorff T, Artale S, Locke JA, Bosso D, Milowsky MI, Witek MS, Battaglia M, Pignata S, Cherhroudi C, Cox ME, De Placido P, Ribera D, Omlin A, Buonocore G, Chi K, Kollmannsberger C, Khalaf D, Facchini G, Sonpavde G, De Placido S, Eigl BJ, Di Lorenzo G. Gordon JA, et al. Among authors: ribera d. Oncotarget. 2018 Apr 13;9(28):19861-19873. doi: 10.18632/oncotarget.24888. eCollection 2018 Apr 13. Oncotarget. 2018. PMID: 29731989 Free PMC article.
11 results